Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Abivax

< Previous 1 2 3 Next >
News headline image
Abivax reports 2023 financial results and operational update
From Abivax
Via GlobeNewswire
News headline image
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
From Abivax
Via GlobeNewswire
News headline image
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
From Abivax
Via GlobeNewswire
News headline image
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
From Abivax
Via GlobeNewswire
News headline image
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
From Abivax
Via GlobeNewswire
News headline image
Abivax 2024 Financial Communication Calendar
From Abivax
Via GlobeNewswire
News headline image
Abivax announces the resumption of its liquidity contract
From Abivax
Via GlobeNewswire
News headline image
Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference
From Abivax
Via GlobeNewswire
News headline image
Abivax Releases the Results of its June 9, 2022 Ordinary Annual and Extraordinary General Meeting
From ABIVAX
Via AccessWire
News headline image
Abivax Phase 2a Study Results of Obefazimod (ABX464) in Rheumatoid Arthritis Published in the Journal "Annals of the Rheumatic Diseases" and Selected for Presentation at EULAR 2022
From ABIVAX
Via AccessWire
News headline image
Abivax Announces Annual Ordinary and Extraordinary General Meeting on June 9, 2022, and the Availability of the Preparatory Documents
From ABIVAX
Via AccessWire
News headline image
Abivax Publishes Universal Registration Document 2022 'Document d'Enregistrement Universel'
From ABIVAX
Via AccessWire
News headline image
Abivax Reports Excellent One-Year Efficacy and Safety Data of ABX464 Phase 2b Maintenance Trial in Ulcerative Colitis
From ABIVAX
Via AccessWire
News headline image
Abivax Reports 2021 Financial Results and Operations Update
From ABIVAX
Via AccessWire
News headline image
Abivax Reports Promising ABX464 Phase 2a One-Year Maintenance Results in Rheumatoid Arthritis
From ABIVAX
Via AccessWire
News headline image
Abivax to host Satellite Symposium at the 17th Congress of ECCO on Feb. 17, 2022
From ABIVAX
Via AccessWire
News headline image
Abivax 2022 Financial Communication Calendar
From ABIVAX
Via AccessWire
News headline image
Abivax's Phase 1/2 Clinical Study Results of ABX196 in Liver Cancer to be Presented on Jan. 21, at ASCO GI Cancers Symposium 2022
From ABIVAX
Via AccessWire
News headline image
Abivax Receives EMA Scientific Advice Supportive of Moving ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis
From ABIVAX
Via AccessWire
News headline image
Abivax to Present at the J.P. Morgan 40th Annual Healthcare Conference
From ABIVAX
Via AccessWire
News headline image
Abivax Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis
From ABIVAX
Via AccessWire
News headline image
Abivax's Phase 1/2 Clinical Study Results of ABX196 in Liver Cancer Show Good Tolerability and Promising Signals of Clinical Benefit and were Selected for Presentation at the ASCO GI Cancers Symposium 2022
From ABIVAX
Via AccessWire
News headline image
ABIVAX: ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance Trial in ulcerative colitis
From ABIVAX
Via AccessWire
News headline image
Abivax Late-Breaking Abstract Presentation and Live Industry Symposium at the UEG Week Virtual 2021
From ABIVAX
Via AccessWire
News headline image
Abivax Presents First-half 2021 Financial Results and Operations Update
From ABIVAX
Via AccessWire
Topics Bonds
News headline image
Abivax Provides an Update on the ABX464 Clinical Data and Development Strategy in Ulcerative Colitis
From ABIVAX
Via AccessWire
Topics Death
News headline image
Abivax Receives Approval for ABX464 Phase 1 Study in Japanese Subjects for Subsequent Inclusion of Japan into the Global Phase 3 Program in Ulcerative Colitis
From ABIVAX
Via AccessWire
News headline image
ABIVAX Announces the Pricing of its Oversubscribed Capital Increase of EUR 60M and Convertible Bonds of EUR 25M, Totaling EUR 85M New Financing
From ABIVAX
Via AccessWire
Topics Bonds Intellectual Property
News headline image
ABIVAX Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50mg ABX464 in Rheumatoid Arthritis
From ABIVAX
Via AccessWire
Topics Death
News headline image
Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3
From ABIVAX
Via AccessWire
Topics Death
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.